By Chris Wack
ImmunityBio shares were up 14% to $3.52 after the company entered into a collaboration and supply agreement with BeiGene.
The two companies will conduct a confirmatory randomized Phase 3 clinical trial, combining BeiGene's tislelizumab and ImmunityBio's Anktiva.
The Phase 3 study aims to confirm the efficacy and safety of the combination, and provide evidence of the potential for these two immunotherapeutic agents to improve overall survival in patients with advanced or metastatic non-small cell lung cancer who have acquired resistance to immune checkpoint inhibitor therapy.
Immunity Bio said that multiple Phase 1 and 2 studies have demonstrated prolonged overall survival with this combination approach, in comparison to historical results with chemotherapy in this patient population.
ImmunityBio will conduct this confirmatory Phase 3 trial globally across multiple sites. When fully enrolled, it is expected to include 462 participants.
The primary endpoint of the study is overall survival, with secondary endpoints including disease control rate, progression-free survival, objective response rate and safety.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
January 29, 2025 10:44 ET (15:44 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。